The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | The importance of MRD monitoring in AML
Peter Valk, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, discusses the importance of measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML). Dr Valk briefly explains how flow cytometry and molecular analyses are used in MRD monitoring and further compares the use of these methods in a clinical setting. To conclude, Dr Valk mentions novel approaches to MRD monitoring, drawing focus on the application of next-generation sequencing (NGS)-based methods. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
